Skip to main content
SpringerLink
Log in

Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence

  • Review Article
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

After an episode of myocardial infarction (MI), patients remain at risk for recurrent ischemic events, heart failure (HF), and sudden death. Post-MI patients with left ventricular systolic dysfunction (LVSD) have an even greater risk of mortality and morbidity. Randomized clinical trials that included post-MI patients with LVSD have demonstrated that pharmacologic therapies aimed at preventing post-MI remodeling with neurohormonal antagonists can significantly improve short- and long-term outcomes, including death, reinfarction, and worsening HF. Recent trials have also demonstrated benefits in terms of cardiovascular event reduction with effective antithrombotic therapies and cholesterol-lowering agents in post-MI setting, especially in patients at very high risk such as those with LVSD. This paper reviews clinical trials that included post-MI patients with LVSD, with or without signs and symptoms of HF, assessing the efficacy of established and emerging pharmacological therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Bahit MC, Kochar A, Granger CB. Post-myocardial infarction heart failure. J Am Coll Cardiol Heart Fail. 2018;6:179–86.

    Google Scholar 

  2. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.

    PubMed  Google Scholar 

  3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the Management of Heart Failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–61.

    PubMed  Google Scholar 

  4. Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119–77.

    PubMed  Google Scholar 

  5. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. ESC Scientific Document Group. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:267–315.

    CAS  PubMed  Google Scholar 

  6. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e139–228.

    PubMed  Google Scholar 

  7. Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67:1235–50.

    PubMed  Google Scholar 

  8. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling et al. J Am Coll Cardiol. 2000;35:569–82.

    CAS  PubMed  Google Scholar 

  9. van der Bijl P, Abou R, Goedemans L, Gersh BJ, Holmes DR Jr, Ajmone Marsan N, et al. Left ventricular post-infarct remodeling implications for systolic function improvement and outcomes in the modern era. JACC Heart Fail. 2020;8:131–40.

    PubMed  Google Scholar 

  10. Gheorghiade M, Fonarow GC. Management of post-myocardial infarction patients with left ventricular systolic dysfunction. Am J Med. 2007;120:109–20.

    PubMed  Google Scholar 

  11. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, López-Sendón J, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109:494–9.

    PubMed  Google Scholar 

  12. Flaherty JD, Bax JJ, De Luca L, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol. 2009;53:254–63.

    PubMed  Google Scholar 

  13. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97:282–9.

    CAS  PubMed  Google Scholar 

  14. Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, et al. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J. 2003;145:73–9.

    PubMed  Google Scholar 

  15. Velazquez EJ, Francis GS, Armstrong PW, et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. Eur Heart J. 2004;25:1911–9.

    PubMed  Google Scholar 

  16. Solomon SD, Zelenkofske S, McMurray JJ, Finn PV, Velazquez E, Ertl G, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med. 2005;352:2581–8.

    CAS  PubMed  Google Scholar 

  17. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106.

    Google Scholar 

  18. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791–800.

    PubMed  Google Scholar 

  19. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al. COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:205–18.

    CAS  PubMed  Google Scholar 

  20. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995;332:80–5.

    CAS  PubMed  Google Scholar 

  21. ISIS-4 Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345669–345685.

  22. GISSI-3 Investigators. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994;343:1115–1122.

  23. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327669–327677.

  24. Study AIRE. Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993;342:821–8.

    Google Scholar 

  25. Torp-Pedersen C, Kober L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 1999;3549–3512.

  26. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high- risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet. 2002;360:752–60.

    CAS  PubMed  Google Scholar 

  27. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893–906.

    CAS  PubMed  Google Scholar 

  28. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med. 1996;335:1001–9.

    CAS  PubMed  Google Scholar 

  29. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.

    Google Scholar 

  30. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–8.

    CAS  PubMed  Google Scholar 

  31. Cannon CP, Braunwald E, McCabe CH, et al. Intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;3:1495–504.

    Google Scholar 

  32. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307–16.

    PubMed  Google Scholar 

  33. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.

    Google Scholar 

  34. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JGF, Cornel JH, et al. CORONA Group: rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61.

    CAS  PubMed  Google Scholar 

  35. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. For the IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.

    CAS  PubMed  Google Scholar 

  36. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.

    CAS  PubMed  Google Scholar 

  37. Beygui F, Cayla G, Roule V, Roubille F, Delarche N, Silvain J, et al. Early aldosterone blockade in acute myocardial infarction. The ALBATROSS Randomized Clinical Trial. J Am Coll Cardiol. 2016;67:1917–27.

    CAS  PubMed  Google Scholar 

  38. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction. Mortality The MIAMI Trial Research Group Am J Cardiol. 1985;56:15G–22G.

    Google Scholar 

  39. Roberts R, Rogers WJ, Mueller HS, Lambrew CT, Diver DJ, Smith HC, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422–37.

    CAS  PubMed  Google Scholar 

  40. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Lopressor Intervention Trial Research Group. Eur Heart J 1987;8:1056–1064, The Lopressor Intervention Trial: Multicentre study of metoprolol in survivors of acute myocardial infarction.

  41. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801–7.

    Google Scholar 

  42. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I Mortality results. JAMA 1982;247:1707–1714.

  43. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II Morbidity results. JAMA 1983;250:2814–2819.

  44. Investigators CAPRICORN. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385–90.

    Google Scholar 

  45. Borghi C, Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the sSurvival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J. 2003;145:80–7.

    CAS  PubMed  Google Scholar 

  46. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med. 2000;342:145–53.

    CAS  PubMed  Google Scholar 

  47. Bertrand ME, Fox KM, Remme WJ, Ferrari R, Simoons ML. Angiotensin-converting enzyme inhibition with perindopril in patients with prior myocardial infarction and/or revascularization: a subgroup analysis of the EUROPA trial. Arch Cardiovasc Dis. 2009;102:89–96.

    PubMed  Google Scholar 

  48. Dézsi CA. Differences in the clinical effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a critical review of the evidence. Am J Cardiovasc Drugs. 2014;14:167–73.

    PubMed  PubMed Central  Google Scholar 

  49. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981;2:823–7.

    CAS  PubMed  Google Scholar 

  50. Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 1983;67:I26–32.

    CAS  PubMed  Google Scholar 

  51. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57–66.

  52. McMurray J, Kober L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol. 2005;45:525–30.

    CAS  PubMed  Google Scholar 

  53. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425–31.

    CAS  PubMed  Google Scholar 

  54. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–17.

    CAS  PubMed  Google Scholar 

  55. Zannad F, McMurray JJV, Krum H, van Veldhuisen D, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.

    CAS  PubMed  Google Scholar 

  56. Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J. 2014;35:2295–302.

    CAS  PubMed  Google Scholar 

  57. Zanchi A, Maillard M, Burnier M. Recent clinical trials with omapatrilat: new developments. Curr Hypertens Rep. 2003;5:346–52.

    PubMed  Google Scholar 

  58. Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015;65:1029–41.

    CAS  PubMed  Google Scholar 

  59. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

    PubMed  Google Scholar 

  60. Torrado J, Cain C, Mauro AG, Romeo F, Ockaili R, Chau VQ, et al. Sacubitril/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits. J Am Coll Cardiol. 2018;72:2342–56.

    CAS  PubMed  Google Scholar 

  61. Koruth JS, Lala A, Pinney S, Reddy VY, Dukkipati SR. The clinical use of Ivabradine. J Am Coll Cardiol. 2017;70:1777–84.

    PubMed  Google Scholar 

  62. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–16.

    CAS  PubMed  Google Scholar 

  63. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. BEAUTIFUL investigators. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372:817–21.

    PubMed  Google Scholar 

  64. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875–885.

  65. Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;2:CD003838.

    Google Scholar 

  66. Tarkin JM, Kaski JC. Trimetazidine: is there a role beyond angina? Eur Heart J Cardiovasc Pharmacother. 2018;4:67–8.

    PubMed  Google Scholar 

  67. Al-Mohammad A. Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction. ESC Heart Fail. 2019;6:878–83.

    PubMed  PubMed Central  Google Scholar 

  68. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.

    CAS  PubMed  Google Scholar 

  69. Åkerblom A, Wojdyla DM, Wallentin L, James SK, de Souza Brito F, Steg PG, et al. PLATO Investigators. Ticagrelor in patients with heart failure after acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J. 2019;213:57–65.

    PubMed  Google Scholar 

  70. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60.

    PubMed  Google Scholar 

  71. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med. 2007;357:2001–15.

    CAS  PubMed  Google Scholar 

  72. Roe MT, Ohman EM, Investigators TRILOGYACS. Prasugrel versus clopidogrel for acute coronary syndromes. N Engl J Med. 2013;368:188–9.

    CAS  PubMed  Google Scholar 

  73. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. ISAR-REACT 5 Trial Investigators. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381:1524–34.

    PubMed  Google Scholar 

  74. Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, et al. COMMANDER HF Investigators. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379:1332–42.

    CAS  PubMed  Google Scholar 

  75. Branch KR, Probstfield JL, Eikelboom JW, Bosch J, Maggioni AP, Cheng RK, et al. Rivaroxaban with or without aspirin in patients with heart failure and chronic coronary or peripheral artery disease. Circulation. 2019;140:529–37.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. He Y, Hu X, Zhou S. Successful COMPASS, disappointing COMMANDER HF, what have we learned from these two trials? J Cardiovasc Pharmacol. 2019;74:306–7.

    CAS  PubMed  Google Scholar 

  77. Kjekshus J, Pedersen TR, Olsson AG, Færgeman O, Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997;3:249–54.

    CAS  PubMed  Google Scholar 

  78. The GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;37:1231–9.

    Google Scholar 

  79. Ridker PM, Everett BM, Thuren T, MacFadyen J, Chang WH, Ballantyne C, et al. CANTOS trial group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017 Sep 21;377(12):1119–31.

    CAS  PubMed  Google Scholar 

  80. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, et al. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 Study. J Am Coll Cardiol. 2006;47:2326–31.

    CAS  PubMed  Google Scholar 

  81. Feinstein MJ, Jhund P, Kang J, Ning H, Maggioni A, Wikstrand J, et al. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. Eur J Heart Fail. 2015;17:434–41.

    CAS  PubMed  Google Scholar 

  82. Zhang S, Zhang L, Sun A, Jiang H, Qian J, Ge J. Efficacy of statin therapy in chronic systolic cardiac insufficiency: a meta-analysis. Eur J Intern Med. 2011;22:478–84.

    CAS  PubMed  Google Scholar 

  83. Morrone D, Weintraub W, Toth P, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223:251–61.

    CAS  PubMed  Google Scholar 

  84. Ambrosy AP, Cerbin LP, Fudim M, Clare RM, Lokhnygina Y, Braunwald E, et al. Natural history of patients postacute coronary syndrome based on heart failure status. Am J Cardiol. 2018;122:1451–8.

    PubMed  Google Scholar 

  85. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.

    CAS  PubMed  Google Scholar 

  86. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.

    CAS  PubMed  Google Scholar 

  87. Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER. Circulation. 2018;138:756–66.

    CAS  PubMed  Google Scholar 

  88. Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74:2452–62.

    CAS  PubMed  Google Scholar 

  89. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New Engl J Med. 2019;381:1995–2008.

    CAS  PubMed  Google Scholar 

  90. Zelniker TA, Braunwald E. Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors. J Am Coll Cardiol. 2020;75:435–47.

    CAS  PubMed  Google Scholar 

  91. Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, et al. Empagliflozin and the risk of heart failure hospitalization in routine clinical care. Circulation. 2019;139:2822–30.

    CAS  PubMed  Google Scholar 

  92. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28.

    CAS  PubMed  Google Scholar 

  93. Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139:1384–95.

    CAS  PubMed  Google Scholar 

  94. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73:1931–44.

    CAS  PubMed  Google Scholar 

  95. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005;96:47G–58G.

    CAS  PubMed  Google Scholar 

  96. Gheorghiade M, Sopko G, De Luca L, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114:1202–13.

    PubMed  Google Scholar 

  97. Teerlink JR, Diaz R, Felker GM. Omecamtiv Mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC Heart Fail. 2020;8:329–40.

    PubMed  Google Scholar 

  98. De Luca L, Piscione F, Colivicchi F, et al. EYESHOT Post-MI Investigators. Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: the EYESHOT post-MI study. Int J Cardiol. 2018;273:8–14.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiosciences, Division of Cardiology, A.O. San Camillo Forlanini, Circonvallazione Gianicolense, 87, 00152, Rome, Italy

    Leonardo De Luca

Authors
  1. Leonardo De Luca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonardo De Luca.

Ethics declarations

Conflict of Interest

None

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

De Luca, L. Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. Cardiovasc Drugs Ther 34, 723–735 (2020). https://doi.org/10.1007/s10557-020-07027-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-020-07027-4

Keywords

Search

Navigation